Clinical Roundup Cancer cells can use backup routes to fuel their growth, Van Andel Institute study finds September 19, 2025Vol.51 No.34
Clinical Roundup Rybrevant + Lazcluze block resistance, extend survival in first-line EGFR-mutated NSCLC, phase III trial shows September 12, 2025Vol.51 No.33
Clinical Roundup Tagrisso + chemo demonstrate OS benefit in EGFR-mutated NSCLC, phase III trial shows September 12, 2025Vol.51 No.33
Clinical Roundup Padcev + Keytruda reach primary endpoint for some bladder cancers, phase III trial shows September 12, 2025Vol.51 No.33
Clinical Roundup NeXT Personal MRD test predicts NSCLC outcomes, phase III trial shows September 12, 2025Vol.51 No.33
Clinical Roundup Pre- and post-surgery immunotherapy combination shows promise for mesothelioma, Johns Hopkins-led study shows September 12, 2025Vol.51 No.33
Clinical Roundup New genetic biomarker flags aggressive brain tumors, Mayo Clinic study finds September 12, 2025Vol.51 No.33
Clinical Roundup Novel tool helps identify key targets to strengthen CAR NK cell therapies, MD Anderson research shows September 12, 2025Vol.51 No.33
Clinical Roundup Cyclin A/B RxL inhibitors restore G1–S-checkpoint in treatment of small cell lung cancer, DFCI research shows September 12, 2025Vol.51 No.33
